# Blueprint Medicines Corporation clinical trials: 32 (2026)

ClinicalTrials.gov lists 32 trials with Blueprint Medicines Corporation as lead sponsor, 6 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Blueprint Medicines Corporation: 32 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/blueprint-medicines-corporation

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 6
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 5, 2026 | NCT07629960 | A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations | Blueprint Medicines Corporation | Phase 1/2 | Recruiting | Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma | 265 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629960) |
| February 5, 2026 | NCT07388511 | A Study of Elenestinib in Healthy Adult Female Participants | Blueprint Medicines Corporation | Phase 1 | Completed | Healthy Participants | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07388511) |
| December 4, 2025 | NCT07264959 | An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM) | Blueprint Medicines Corporation | Observational | Recruiting | Indolent Systemic Mastocytosis | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07264959) |
| December 1, 2025 | NCT07255638 | A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany | Blueprint Medicines Corporation | Observational | Recruiting | Indolent Systemic Mastocytosis | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07255638) |
| August 27, 2025 | NCT07143669 | Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations | Blueprint Medicines Corporation | Observational | Recruiting | Clonal Mast Cell Disease, KIT D816V Mutation, Suspected KITD816V Mutated Clonal Mast Cell Disease | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07143669) |
| April 28, 2025 | NCT06948032 | Study of BLU-808 in Healthy Adult Participants | Blueprint Medicines Corporation | Phase 1 | Completed | Healthy Participants | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06948032) |
| April 17, 2025 | NCT06931405 | Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) | Blueprint Medicines Corporation | Phase 2 | Active not recruiting | Chronic Inducible Urticaria, Chronic Spontaneous Urticaria | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06931405) |
| April 10, 2025 | NCT06922448 | Study of BLU-808 in Allergic Rhinoconjunctivitis | Blueprint Medicines Corporation | Phase 2 | Completed | Allergic Rhinoconjunctivitis | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06922448) |
| December 24, 2024 | NCT06748001 | Avapritinib Rollover Study | Blueprint Medicines Corporation | Phase 4 | Recruiting | Mastocytosis, Systemic | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06748001) |
| November 8, 2022 | NCT05609942 | Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies | Blueprint Medicines Corporation | Phase 1 | Terminated | Advanced Systemic Mastocytosis | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05609942) |
| February 23, 2022 | NCT05252416 | (VELA) Study of BLU-222 in Advanced Solid Tumors | Blueprint Medicines Corporation | Phase 1 | Terminated | Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05252416) |
| February 16, 2022 | NCT05241873 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | Blueprint Medicines Corporation | Phase 1 | Terminated | Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site... | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05241873) |
| December 10, 2021 | NCT05153408 | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | Blueprint Medicines Corporation | Phase 1 | Terminated | Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05153408) |
| June 2, 2021 | NCT04910685 | (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | Blueprint Medicines Corporation | Phase 2/3 | Recruiting | Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis | 534 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04910685) |
| June 1, 2021 | NCT04908176 | A Drug-drug Interaction Study of Avapritinib and Midazolam | Blueprint Medicines Corporation | Phase 1 | Completed | Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors, Recurrent or Unresectable Central Nervous... | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04908176) |
| April 28, 2021 | NCT04862780 | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | Blueprint Medicines Corporation | Phase 1 | Terminated | Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung... | 177 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04862780) |
| April 1, 2021 | NCT04825574 | Study for Patients Previously Treated in Avapritinib Clinical Trials | Blueprint Medicines Corporation | Phase 4 | Completed | Gastrointestinal Stromal Tumors | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04825574) |
| March 23, 2021 | NCT04811365 | (PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation | Blueprint Medicines Corporation | Observational | Completed | Systemic Mast Cell Activation, KIT D816V Mutation | 379 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04811365) |
| February 26, 2021 | NCT04773782 | A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling | Blueprint Medicines Corporation | Phase 1/2 | Completed | Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm, CNS Tumor | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04773782) |
| January 19, 2021 | NCT04714086 | Expanded Access Program for Avapritinib | Blueprint Medicines Corporation | Not applicable | No longer available | Solid Tumors | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04714086) |
| January 6, 2021 | NCT04697446 | External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive... | Blueprint Medicines Corporation | Observational | Unknown | RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms... | 279 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04697446) |
| January 5, 2021 | NCT04695431 | Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM | Blueprint Medicines Corporation | Observational | Completed | Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated... | 317 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04695431) |
| December 19, 2019 | NCT04204928 | Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC | Blueprint Medicines Corporation | Not applicable | Approved for marketing | Non-Small Cell Lung Cancer, Medullary Thyroid Cancer | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04204928) |
| March 5, 2019 | NCT03862885 | Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST | Blueprint Medicines Corporation | Not applicable | Approved for marketing | GIST | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03862885) |
| February 28, 2019 | NCT03858075 | Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults | Blueprint Medicines Corporation | Phase 1 | Completed | Healthy Volunteers | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03858075) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 12 |
| Phase 1/2 | 2 |
| Phase 2 | 4 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Phase 4 | 2 |
| Not applicable | 3 |
| Observational | 7 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 15 |
| Recruiting | 6 |
| Terminated | 5 |
| Active not recruiting | 2 |
| Approved for marketing | 2 |
| No longer available | 1 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Mastocytosis, Systemic | 10 |
| Carcinoma, Non-Small-Cell Lung | 6 |
| Lung Neoplasms | 5 |
| Neoplasms | 5 |
| Leukemia, Mast-Cell | 5 |
| Gastrointestinal Stromal Tumors | 5 |
| Mastocytosis | 4 |
| Respiratory Tract Neoplasms | 4 |
| Neoplasms by Site | 4 |
| Lung Diseases | 4 |
| Respiratory Tract Diseases | 4 |
| Carcinoma, Bronchogenic | 4 |
| Carcinoma | 4 |
| Neoplasms by Histologic Type | 4 |
| Thoracic Neoplasms | 4 |
| Bronchial Neoplasms | 3 |
| Adenocarcinoma | 3 |
| Neoplasms, Nerve Tissue | 3 |
| Recurrence | 3 |
| Glioma | 2 |
| Mastocytosis, Cutaneous | 2 |
| Carcinoma, Hepatocellular | 1 |
| Liver Neoplasms | 1 |
| Liver Diseases | 1 |
| Brain Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pediatric dentistry practices in the United States](https://specstream.ai/data/businesses/pediatric-dentistry-practices/united-states)
- [Water purification companies in the United States](https://specstream.ai/data/businesses/water-purification-companies/united-states)
- [Corporate gift suppliers in the United States](https://specstream.ai/data/businesses/corporate-gift-suppliers/united-states)
- [Iron fabricators in the United States](https://specstream.ai/data/businesses/iron-fabricators/united-states)
- [Roofing contractors in the United States](https://specstream.ai/data/businesses/roofing-contractors/united-states)
- [B2B food products companies in the United States](https://specstream.ai/data/businesses/b2b-food-products-companies/united-states)
